February 15, 2018

FDA permits marketing of new blood test for concussions

Editor's Note

The Food & Drug Administration (FDA) on February 14 authorized marketing of the first blood test to help evaluate concussions in adults and reduce the need for CT scans.

The Banyan Brain Trauma Indicator works by measuring levels of proteins (ie, UCH-L1 and GFAP) that are released from the brain into the patient’s blood within 12 hours of a head injury.

In studies, the Brain Trauma Indicator was able to predict the presence of intracranial lesions 97.5% of the time and those who did not have intracranial lesions 99.6% of the time.

 

Read More >>

Join our community

Learn More
Video Spotlight
Live chat by BoldChat